Adverse events in faecal microbiota transplant: a review of the literature

Baxter, M.; Colville, A.

doi:10.1016/j.jhin.2015.10.024

Cited by 162 publications

(138 citation statements)

References 110 publications

(351 reference statements)

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…Whereas vancomycin only cured 31% of patients, FMT cured 81% of patients after a single infusion and 94% of patients after repeated infusion [105]. Other possible indications for FMT include irritable bowel syndrome, inflammatory bowel disease, constipation, and metabolic syndrome [106].…”

Section: Fecal Microbiota Transplantationmentioning

confidence: 99%

See 1 more Smart Citation

The intestinal microbiota, energy balance, and malnutrition: emphasis on the role of short-chain fatty acids

Fluitman

Clercq

Keijser

et al. 2017

Expert Review of Endocrinology & Metabolism

View full text Add to dashboard Cite

Introduction: Malnutrition refers to both over-and undernutrition and results from a disruption in energy balance. It affects one in three people worldwide and is associated with increased morbidity and mortality. The intestinal microbiota represents a newly identified factor that might contribute to the development of malnutrition, as it harbors traits that complement the human metabolic and endocrine capabilities, thereby influencing energy balance. Areas covered: In the current review, we aim to give a comprehensive overview on the microbiota, its development and its possible influence on energy balance, with emphasis the role of short-chain fatty acids. We also consider microbial characteristics associated with obesity and undernutrition and evaluate microbial manipulating strategies. The PubMed database was searched using the terms:

show abstract

Section: Fecal Microbiota Transplantationmentioning

confidence: 99%

“…FMT-related adverse events are rare, generally mild and self-limiting, and mostly constitute gastrointestinal discomfort. Serious adverse events that were reported included bacteremia, perforations, and death and occurred in patients who were severely ill prior to FMT [106].…”

Section: Fecal Microbiota Transplantationmentioning

confidence: 99%

The intestinal microbiota, energy balance, and malnutrition: emphasis on the role of short-chain fatty acids

Fluitman

Clercq

Keijser

et al. 2017

Expert Review of Endocrinology & Metabolism

View full text Add to dashboard Cite

show abstract

“…1 190 réalisées pour infections à Clostridium difficile [26]. La plupart des effets secondaires observés sont surtout digestifs avec environ 75 % des patients qui présentent des diarrhées et 50 % qui déclarent avoir des douleurs abdominales dans les heures suivant la transplantation fécale.…”

Section: Progrès Techniquesunclassified

“…Un faible nombre de patients disent souffrir de constipation à la suite de la greffe. Les effets secondaires graves comme des bactériémies causées par des entérobactéries, parfois fatales, ou des perforations intestinales, sont rares [26,27]. Deux cas d'infections à norovirus 5 ont été documentés [26].…”

Section: Progrès Techniquesunclassified

Greffe de microbiote fécal et infections

Lagier

Raoult

2016

Med Sci (Paris)

View full text Add to dashboard Cite

“…Th e use of frozen FMT capsules simplifi es administration while obviating any invasive procedures, thus further increasing cost eff ectiveness and safety ( 10,11 ). Two recently published reviews assessing the safety of FMT concluded that most serious adverse events reported were procedure related ( 12,13 ). Storage of frozen capsules is still limited to −80 °C, necessitating on-site administration or cumbersome (and costly) delivery on dry ice.…”

mentioning

confidence: 99%

Editorial: Making Fecal Microbiota Transplantation Easier to Swallow: Freeze-Dried Preparation for Recurrent Clostridium difficile Infections

Youngster

Gerding

2017

American Journal of Gastroenterology

View full text Add to dashboard Cite

Fecal microbiota transplant (FMT) has emerged as an effective and increasingly popular therapy for recurrent Clostridium diffi cile infections in patients that have failed standard antimicrobial treatment. Patient access to FMT is hampered by the logistics of manufacturing, storing, and delivering the inocula. An observational study describes the development and clinical effi cacy of freeze-dried FMT capsules for oral administration. While awaiting the emergence of defi ned bacterial therapeutics for Clostridium diffi cile infections, this refi nement of FMT is an encouraging step toward simplifying FMT treatment. Randomized controlled trials are required to further establish the effi cacy and safety of lyophilized FMT. Am J Gastroenterol 2017; 112:948-950; doi: 10.1038/ajg.2017 In recent years, as the important roles of gut microbiota in human physiology are coming to light, fecal microbiota transplantation (FMT), i.e., the transfer of fecal microbes from a donor to a patient, has emerged as an eff ective and increasingly popular therapy for recurrent Clostridium diffi cile infections (CDI) ( 1 ). Th e evolving epidemiology of CDI has focused interest on "non-traditional" treatment modalities, as the disease has established itself as a major cause of both healthcare and communityacquired morbidity and mortality ( 2 ). Suboptimal response to standard antimicrobial treatment with metronidazole, vancomycin, and even fi daxomicin is common, resulting in CDI recurrences in up to 30% of patients ( 3 ). Initial CDI recurrences are followed by even higher recurrence rates. Prolonged vancomycin taper/pulse therapy is oft en administered and is up to 58% eff ective in this multiple recurrence population ( 4 ), leaving a growing number of patients and providers in search of alternative treatment options. Although not an U.S. Food and Drug Administration-approved treatment, randomized controlled trials are being increasingly reported ( 4-9 ) and generally show success rates (prevention of further recurrent CDI) of 70% or greater, although rates for a single FMT via the enema route are lower if a modifi ed intent-to-treat (mITT) end point is used ( 4,9 ). Despite lack of U.S. Food and Drug Administration approval, FMT has rapidly become an accepted treatment for recurrent CDI that has not responded to standard treatments. Most offi cial treatment guidelines of gastroenterology and infectious diseases associations in the US, Canada, Europe, and Australia include FMT as at least an alternative therapy.Nevertheless, access to FMT is still hampered by the logistics of donor selection and screening, processing of the inoculum, and delivery to the colon. In the past 2 years, several important advances have been made in an eff ort to make FMT accessible to a wider population of patients. First, though frozen FMT has been used for some time, it was only recently that Lee et al. ( 9 ) showed clinical non-inferiority in a randomized controlled study using enemas, although response rates varied widely depending upon the num...

show abstract

Adverse events in faecal microbiota transplant: a review of the literature

Cited by 162 publications

References 110 publications

The intestinal microbiota, energy balance, and malnutrition: emphasis on the role of short-chain fatty acids

The intestinal microbiota, energy balance, and malnutrition: emphasis on the role of short-chain fatty acids

Greffe de microbiote fécal et infections

Editorial: Making Fecal Microbiota Transplantation Easier to Swallow: Freeze-Dried Preparation for Recurrent Clostridium difficile Infections

Contact Info

Product

Resources

About